H19 promotes non‐small‐cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR‐17

  • Zhiwen Huang
    Department of Respiratory Medicine The First Affiliated Hospital of Soochow University Suzhou Jiangsu China
  • Wei Lei
    Department of Respiratory Medicine The First Affiliated Hospital of Soochow University Suzhou Jiangsu China
  • Hai‐Bo Hu
    Department of Respiratory Medicine Affiliated Renhe Hospital of China Three Gorges University Yichang Hubei China
  • Hongyan Zhang
    Department of Respiratory Medicine Affiliated Renhe Hospital of China Three Gorges University Yichang Hubei China
  • Yehan Zhu
    Department of Respiratory Medicine The First Affiliated Hospital of Soochow University Suzhou Jiangsu China

説明

<jats:sec><jats:label /><jats:p>LncRNAs can exhibit crucial roles in the development of multiple cancers, including non‐small cell lung cancer (NSCLC). Currently, we investigated the role of lncRNA H19 in NSCLC. In our study, it was found that H19 was upregulated in A549 and H1299 cells compared to normal lung epithelial BEAS‐2B cells. Meanwhile, we observed that miR‐17 was downregulated in NSCLC cell lines. Inhibited H19 can suppress the growth, migration, and invasion of NSCLC cells and bioinformatics search was performed to predict the correlation between H19 and miR‐17. Overexpression of miR‐17 was able to inhibit the progression of NSCLC cells while reversely miR‐17 inhibitors reversed this process. In addition, signal transducers and activators of transcription (STAT3), as an mRNA target of miR‐17, was presented in our research. Moreover, we discovered that H19 demonstrated its biological functions via regulating miR‐17 and STAT3 in vitro. Silencing H19 greatly increased STAT3 expression by sponging miR‐19 in vitro. It was hypothesized that H19 may serve as a competing endogenous RNA (ceRNA) to modulate STAT3 by attaching miR‐17 in lung cancer. In summary, our findings indicated that H19/miR‐17/STAT3 axis participated in NSCLC development. H19 could be regarded as a significant prognostic biomarker in NSCLC progression.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ